The significance of estrogen metabolism for hormone-dependent neoplasias from the clinical-pharmacological aspect;Beurteilung des estrogen-metabolismus bei hormonabhangigen neoplasien unter klinischpharmakologischen aspekten

Arzneimittel-Forschung/Drug Research

Volumn 49, Issue 8, 1999, Pages 649-662

  Lippert, Theodor H ^a   Seeger, Harald ^a   Mueck, Alfred O ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

16 Hydroxyestrone; 2 Hydroxyestrone; 2 Methoxyestradiol; Estradiol, metabolites; Hormone dependent cancer, significance of estrogen

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 HYDROXYESTRONE; 2 METHOXYESTRADIOL; DRUG METABOLITE; ESTRADIOL; ESTROGEN DERIVATIVE;

BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; ESTROGEN ACTIVITY; ESTROGEN METABOLISM; HORMONE METABOLISM; HORMONE SUBSTITUTION; HUMAN; NONHUMAN; REVIEW;

EID: 0032784991     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1300478     Document Type: Review

References (123)

1. [1] Beatson, G. T., On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet II, 104 (1896)
2. [2] Gordon, S., Cantrall, E. W., Cekleniak, W. P. et al., Steroid and lipid metabolism. The hypocholesteremic effect of estrogen metabolites. Steroids 4, 267 (1964)
3. [3] Lippert, T. H., Seeger, H., Mueck, A. O., Metabolism of endogenous estrogens, in: Estrogens and Antiestrogens - Handbook of Experimental Pharmacology, M. Oettel, E. Schillinger (eds.), Springer Verlag, Berlin, im Druck
4. [4] Fishman, J., Bradlow, H. L., Gallagher, T. F., Oxidative metabolism of estradiol. J. Biol. Chem. 235, 3104 (1960)
5. [5] Martucci, C. P., Fishman, J., P450 enzymes of estrogen metabolism. Pharmacol. Ther. 57, 237 (1993)
6. [6] Zhu, B. T., Conney, A. H., Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 19, 1 (1998)
7. [7] Siiteri, P. K., MacDonald, P. C., Role of extraglandular estrogen in human endocrinology, in: Handbook of Physiology. R. O. Greep, E. B. Astwood (eds), pp 615-630, American Physiological Society, Washington DC (1973)
8. [7a] Knight, W. M., Estrogens administered to food-producing animals: Environmental considerations, in: Estrogens in the environment, J.A. McLachlan (ed), pp 391-401, Elsevier/North-Holland (1980)
9. [8] Ikegawa, S., Lahita, R., Fishman, J., Concentration of 16α-hydroxyestrone in human plasma as measured by a specific RIA. J. Steroid Biochem. 18, 329 (1983)
10. [9] Adlercreutz, H., Martin, F., Lindström, B., Gas chromatographic and mass spectometric studies on oestrogens in bile - 2. Men and nonpregnant women. J. Steroid Biochem. 9, 1197 (1978)
11. [10] Adlercreutz, H., Tikkanen, M. J., Hunneman, D. H., Mass fragmentographic determination of eleven estrogens in the body fluids of pregnant and nonpregnant subjects. J. Steroid Biochem. 5, 211 (1974)
12. [11] Naganuma, H., Hershcopf, R. J., Michnovicz, J. J. et al., Radioimmunoassay of 16α-hydroxyestrone in human urine. Steroids 53, 37 (1989)
13. [12] Longcope, C., Pratt, J. H., Relationship between urine and plasma estrogen ratios. Cancer Res. 38, 4025 (1978)
14. [13] Lonning, P. E., Skulstad, P., Sunde, A. et al., Separation of urinary metabolites of radiolabelled estrogens in man by HPLC. J. Steroid Biochem. 32, 91 (1989)
15. [14] Nocke, W., Breuer, H., Knuppen, R., Isolierung und quantitative Bestimmung der 4 Epimeren Estriole nach Injektion von 16α-und 16β-Hydroxyöstron beim Menschen. Acta Endocrinol. 36, 393 (1961)
16. [15] Adlercreutz, H., Martin, M., Pulkkinen, M. et al., Intestinal metabolism of estrogens. J. Clin. Endocrinol. Metab. 43, 497 (1976)
17. [16] Fishman, J., Martucci, C., Biological properties of 16α-hydroxyestrone: Implications in estrogen physiology and pathophysiology. J. Clin. Endocrinol. Metabol. 51, 611 (1980)
18. [17] Loukovaara, M., Carson, M., Adlercreutz, H., Regulation of sex-hormone-binding globulin production by endogenous estrogens in vitro. Biochem. Biophys. Res. Commun. 206, 895 (1995)
19. [18] Seeger, H., Mueck, A. O., Lippert, T. H., Effect of estradiol metabolites on prostacyclin synthesis in human endothelial cell cultures. Life Sci., in press
20. [19] Seeger, H., Mueck, A. O., Lippert, T. H., Effect of estradiol metabolites on the susceptibility of low density lipoprotein to oxidation. Life Sci. 61, 856 (1997)
21. [20] Seeger, H., Mueck, A. O., Lippert, T. H., The antiproliferative effect of 17β-estradiol metabolites on human coronary artery smooth muscle cells. Med. Sci. Res. 26, 481 (1998)
22. [21] Bucala, R., Fishman. J., Cerami, A., Formation of covalent adducts between cortisol and 16α-hydroxyestrone and protein: Possible role in the pathogenesis of cortisol toxicity and systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA 79, 3320 (1982)
23. [22] Bucala, R., Fishman, J., Cerami, A., The reaction of 16α-hydroxyestrone with erythrocytes in vitro and in vivo. Eur. J. Biochem. 140, 593 (1984)
24. [23] Yu, S. C., Fishman, J., Interaction of histones with estrogens. Covalent adduct formation with 16α-hydroxyestrone. Biochemistry 24, 8017 (1985)
25. [24] Bucala, R., Lahita, R. G., Fishman, J. et al., Increased levels of 16α-hydroxyestrone-modified proteins in pregnancy and in systemic lupus erythematosus. J. Clin. Endocrinol. Metab. 60, 841 (1985)
26. [25] Swaneck, G. E., Fishman, J., Covalent binding of the endogenous estrogen 16α-hydroxyestrone to estradiol receptor in human breast cancer cells: Characterization and intranuclear localization. Proc. Natl. Acad. Sci. USA 85, 7831 (1988)
27. [26] Telang, N. T., Bradlow, H. L., Kurihara, H. et al., In vitro biotransformation of estradiol by explant cultures of murine mammary tissues. Breast Cancer Res. Treat. 13, 173 (1989)
28. [27] Suto, A., Bradlow, H. L., Wong, G. Y. et al., Persistent estrogen responsiveness of ras oncogene-transformed mouse mammary epithelial cells. Steroids 57, 262 (1992)
29. [28] Telang, N. T., Narayanan, R., Bradlow, H. L., Osborne, M. P., Coordinated expression of intermediate biomarkers for tumorigenic transformation in ras-transfected mouse mammary epithelial cells. Breast Cancer Res. Treat. 18, 155 (1991)
30. [29] Telang, N. T., Kurihara, H., Wong, G. Y. et al., Preneoplastic transformation in mouse mammary tissue: Identification and validation of intermediate biomarkers for chemoprevention. Anticancer Res. 11, 1021 (1991)
31. [30] Suto, A., Bradlow, H. L., Wong, G. Y. et al., Experimental down-regulation of intermediate biomarkers of carcinogenesis in mouse mammary cells. Breast Cancer Res. Treat. 27, 193 (1993)
32. [31] Telang, N. T., Suto, A., Bradlow, H. L. et al., Genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. Rec. Progr. Horm. Res. 48, 481 (1993)
33. [32] Telang, N. T., Suto, A., Wong, G. Y. et al., Induction of 16α-hydroxylase of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J. Natl. Cancer Inst. 84, 634 (1992)
34. [33] Osborne, M. P., Bradlow, H. L., Wong, G. Y. et al., Upregulation of estradiol 16α-hydroxylation in human breast tissue: Potential biomarker of breast cancer risk. J. Natl. Cancer Inst. 85, 1917 (1993)
35. [34] Niwa, T., Bradlow, H. L., Fishman, J. et al., Induction and inhibition of estradiol hydroxylase activities in MCF-7 human breast cancer cells in culture. Steroids 55, 297 (1990)
36. [35] Swaneck, G. E., Fishman, J., Effects of estrogens in MCF-7 cells: positive or negative regulation by the nature of the ligand-receptor complex. Biochem. Biophys. Res. Comm. 174, 276 (1991)
37. [36] Suto, A., Bradlow, H. L., Kubota, T. et al., Alteration in proliferation and endocrine responsiveness of human mammary carcinoma cells by prototypic tumor-suppressing agents. Steroids 58, 215 (1993)
38. [37] Bradlow, H. L., Davis, D. L., Lin, G. et al., Effects of pesticides on the ratio of 16α/2 hydoxyestrone: A biological marker of breast cancer risk. Environ. Health Perspect. 103 (Suppl. 7), 147 (1995)
39. [38] Bradlow, H. L., Hershcopf, R. J., Martucci, C. P. et al., Estradiol 16α-hydroxylation in the mouse correlates with tumor incidence and presence of murine mammary tumor virus: A possible model for the hormonal etiology of breast cancer in humans. Proc. Natl. Acad. Sci. USA 82, 6295 (1985)
40. [39] Lustig, R. H., Mobbs, C. V., Bradlow, H. L. et al., Differential effects of estradiol and 16α-hydroxyestrone on pituitary and preoptic estrogen receptor regulation. Endocrinology 125, 2701 (1989)
41. [40] Barlow, J. J., Logan, C. M., Estrogen secretion, biosynthesis and metabolism: their relationship to the menstrual cycle. Steroids 7, 309 (1966)
42. [41] Dinnendahl, V., Fricke, U., Estriol. In: Arzneistoff-Profile. pp 1-9, Govi-Verlag, Frankfurt (1991)
43. [42] Clark, J. H., Paszko, Z., Peck, E. J., Nuclear binding and retention of the receptor estrogen complex:relation to the agonistic and antagonistic properties of estriol. Endocrinology 100, 91 (1977)
44. [43] Clark, J. H., Markaverich, B. M., The agonistic and antagonistic effects of short acting estrogens: a review. Pharmac. Ther. 21, 429 (1983)
45. [44] Lemon, H. M., Wotiz, H. H., Parson, L., et al., Reduced estriol excretion in patients with breast cancer prior to endocrine therapy. J. Am. Med. Assoc. 196, 1128 (1966)
46. [45] Dao, T. L., Metabolism of estrogens in breast cancer. Biochim. Biophys. Acta 560, 397 (1979)
47. [46] Rudali, G., Apiou, F., Muel, B., Mammary cancer produced in mice with estriol. Eur. J. Cancer 11, 39 41, 1975
48. [47] Kawatsu, R., Ezaki, T., Kotam, M. et al., Growth promoting effect of oestriol in a lymphoma lacking oestrogen receptors. Br. J. Cancer 59, 563 (1989)
49. [48] Reddel, R. R., Sutherland, R. L., Effect of pharmacological concentrations of estrogens on proliferation and cell cycle kinetics of human breast cancer cell lines in vitro. Cancer Res. 47, 5323 (1987)
50. [49] Longcope, C., Femino, A., Flood, C. et al., Metabolic clearance rate and conversion ratios of 3H-hydroxyestrone in normal men. J. Clin. Endocrinol. Metab. 54, 374 (1982)
51. [50] Merriam, G. R., Brandon, D. D., Kono, S. et al., Rapid metabolic clearance of the catecholestrogen 2-hydroxyestrone. J. Clin. Endocrinol. Metab 51; 1211 (1980)
52. [51] Longcope, C., Flood, C., Femino, A. et al., Metabolism of 2-methoxyestrone in normal men. J. Clin. Endocrinol. Metab. 57, 277 (1983)
53. [52] Bates, G. W., Edman, C. D., Porter, J. C. et al., Metabolism of catecholestrogen by human erythrocytes. J. Clin. Endocrinol. Metab. 45, 1120 (1977)
54. [53] Schneider, J., Huh, M. M., Bradlow, H. L. et al., Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast cancer cells. J. Biol. Chem. 259, 4840 (1984)
55. [54] Grohe, C., Kahlert, S., Lobbert, R. et al., Modulation of hypertensive heart diseases by estrogen. Steroids 61, 201 (1996)
56. [55] Vandewalle, B., Lefebre, J., Opposite effects of estrogen and catecholestrogen on hormone-sensitive breast cancer cell growth and differentiation. Mol. Cell. Endocrinol. 61, 239 (1989)
57. [56] Li, S. A., Prudy, R. H., Li, J. J., Variations in catechol-O-methyltransferase activity in rodent tissues: possible role in estrogen carcinogenicity. Carcinogenesis 10, 63 (1989)
58. [57] Faber, E., Ghoshal, A. K., Lipotropes and chemical carcinogenesis, in: Nutrition and Chemical Toxicity, C. Joannides (ed.), pp 219-235, John Wiley and Sons, Chichester (1998)
59. [58] Berg, D., Sonsalla, R., Kuss, E., Concentrations of 2-methoxyoestrogens in human sera measured by a heterologous immunoassay with an 1251-labelled ligand. Acta Endocrinol. 103, 282 (1983)
60. [59] Berg, D., Thaler, F., Kuss, E., Concentrations of 2-hydroxyoestrogens in human sera measured by a heterologous immunoassay with an 1251-labelled ligand. Acta Endocrinol. 100, 154 (1982)
61. [60] Martucci, C. P., Fishman, J., Impact of continuously administered catechol estrogens on uterine growth and luteinizing hormone secretion. Endocrinology 105, 1288 (1979)
62. [61] Rogerson, B. J., Eagon, P. K., A male specific hepatic estrogen binding protein: characteristics and binding properties. Arch. Biochem. Biophys. 250, 70 (1986)
63. [62] Dunn, J. F., Merriam, G. R., Eil, C. et al., Testosterone-estradiol binding globulin binds to 2-methoxyestradiol with greater affinity than to testosterone. J. Clin. Endocrinol. Metab. 51, 404 (1980)
64. [63] Fotsis, T., Zhang, Y., Pepper, M. S. et al., The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368, 237 (1994)
65. [64] Klauber, N., Parangi, S., Flynn, E. et al., Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 57, 81 (1997)
66. [65] Yue, T. L., Wang, X., Louden, C. S. et al., 2-Methoxyestradiol, an endogenous estrogen metabolite induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression. Mol. Pharmacol. 51, 951 (1997)
67. [66] Tsukamoto, A., Kaneko, Y., Yoshida, T. et al., 2-Methoxyestradiol, an endogenous metabolite of estrogen, enhances apoptosis and beta-galactosidase expression in vascular endothelial cells. Biochem. Biophys. Res. Commun. 248, 9 (1998)
68. [67] Nishigaki, I., Sasaguri, Y., Yagi, K., Antiproliferative effect of 2-methoxyestradiol on cultured smooth muscle cells from rabbit aorta. Atherosclerosis 113, 167 (1995)
69. [68] Dubey, R. K., Gillespie, D. G., Jackson, E. K., 17 Beta-estradiol, its metabolites, and progesterone inhibit cardiac fibroblast growth. Hypertension 31, 522 (1998)
70. [69] Pico, C., Puigserver, P., Oliver, P. et al., 2-Methoxyestradiol, an endogenous metabolite of 17beta-estradiol, inhibits adipocyte proliferation. Mol. Cell. Biochem. 189, 1 (1998)
71. [70] Spicer, L. J., Hammond, J. M., Catecholestrogens inhibit proliferation and DNA synthesis of porcine granulosa cells in vitro: Comparison with estradiol, 5alpha-dihydrotestosterone, gonadotropins and catecholamines. Mol. Cell. Endocrinol. 64, 119 (1989)
72. [71] Cushman, M., He, H. M., Katzenellenbogen, J. A. et al.. Synthesis, antitubulin and antimitotic activity and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicin binding site. J. Med. Chem. 38, 2041 (1995)
73. [72] Kataoka, M., Schumacher, G., Cristiano, R. J. et al., An agent that increases tumor suppressor transgene product coupeld with systemic transgene delivery inhibits growth of metastalic lung cancer in vivo. Cancer Res. 58, 4761 (1998)
74. [73] Maxwell, S. A., Roth, J. A., Mukhopadhyay, T., Analysis of phosphorylated isoforms of the p53 tumor suppressor protein in human lung carcinoma cells undergoing apoptosis. Electrophoresis 17, 1772 (1996)
75. [74] Mukhopadhyay, T., Roth, J. A., Induction of apoptosis inhuman lung cancer cells after wild type p53 activation by 2-methoxyestradiol. Oncogene 14, 379 (1997)
76. [75] Mukhopadhyay, T., Roth, J. A., Superinduction of wild type p53 protein after 2-methoxyestradiol treatment of Adp53 transduced cell induces tumor cell apoptosis. Oncogene 17, 241 (1998)
77. [76] Nakagawa-Yagi, Y., Ogane, N., Inoki, Y. et al., The endogenous estrogen metabolite 2-methoxyestradiol induces apoptotic neural cell death in vitro. Life Sci. 58, 1461 (1996)
78. [77] Lottering, M. L., de Kock, M., Viljoen, T. C. et al., 17 beta-estradiol metabolites affect some regulators of the MCF-7 cell cycles. Cancer Lett. 110, 181 (1996)
79. [78] Lottering, M. L., Haag, M., Seegers, J. C., Effects of 17 beta estradiol metabolites on cell cycle events in MCF-7 cells. Cancer Res. 52, 5926 (1992)
80. [79] Seegers, J. C., Aveling, M. L., van Aswegen, C. H. et al., The cytotoxic effects of estradiol 17ß, catecholestradiols and methoxyestradiols on dividing MCF-7 and HeLa cells. J. Steroid Biochem. 32, 797 (1989)
81. [80] Seegers, J. C., Lottering, M. L., Grobler, C. J. et al., The mammalian metabolite, 2-methoxyestradiol, affects p53 levels and apoptosis induction in transformed cells, but not in normal cells. J. Steroid Biochem. Mol. Biol. 62, 253 (1997)
82. [81] Attalla, H., Mäkelä, T. P., Adlercreutz, H. et al., 2-methoxyestradiol arrests cells in mitosis without depolymerizing tubulin. Biochem. Biopyhs. Res. Com. 228, 467 (1996)
83. [82] Attalla, H., Westberg, J. A., Andersson, L. C. et al., 2-methoxyestradiol-induced phosphorylation of Bcl-2: Uncoupling from JNK/SAPK activation. Biochem. Biophys. Res. Com. 247, 616 (1998)
84. [83] D'Amato, R., Lin, C. M., Flynn, E. et al., 2-methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc. Natl. Acad. Sci. USA 91, 3964 (1994)
85. [84] Hamel, E., Lin, C. M., Flynn, E. et al., Interactions of 2-methoxyestradiol, an endogenous mammalian metabolite, with unpolymerized tubulin and with tubulin polymers. Biochemistry 35, 1304 (1996)
86. [85] Blood, C. H., Zetter, B. R., Tumor interaction with the vasculature: Angiogenesis and tumor metastasis. Biochim. Biophys. Acta 1032, 89 (1999)
87. [86] Folkman, J., Watson, K., Ingber, D. E. et al., Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339, 58 (1989)
88. [87] Abul-Hajj, Y. J., Effect of catechol estrogens on rat mammary tumors. Cancer Res. 39, 4882 (1979)
89. [88] Lamberts, S. W., Nagy, J., Uitterlinden, P. et al., The effect of catecholestrogens on the growth of prolactin-secreting pituitary tumors and normal prolactin synthesis in the rat. Endocrinology 110, 1141 (1982)
90. [89] Emons, G., Ball, P., Knuppen, R., Radioimmunoassays of catechol estogens, in: Catechol Estrogens, G. R. Merriam, M. B. Lipsett MB (eds), pp 151-165, Raven, New York (1983)
91. [90] Fishman, J., Martucci, C., Dissociation of biological activities in metabolites of estradiol, in: Estrogens in the environment, J. A. McLachlan (ed), pp 131-145, Elsevier/North-Holland (1980)
92. [91] Schütze, N., Vollmer, G., Tiemann, I. et al., Catecholestrogens are MCF-7 cell estrogen receptor agonists. J. Steroid Biochem. Mol. Biol. 46, 781 (1993)
93. [92] Yager, J. D., Liehr, J. G., Molecular mechanisms of estrogen carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 36, 203 (1996)
94. [93] Liehr, J. G., Roy, D., Free radical generation by redox cycling of estrogens. Free Radic. Biol. Med. 8, 415 (1990)
95. [94] Floyd, R. A., The role of 8-hydroxyguanine in carcinogenesis. Carcinogenesis 11, 1447 (1990)
96. [95] Han, X., Liehr, J. G., 8-hydroxylation of guanine bases in kidney and liver DNA of hamsters treated with estradiol: role of free radicals in estrogen-induced carcinogenesis. Cancer Res. 54, 5515 (1994)
97. [96] Han, X., Liehr, J. G., Microsome-mediated 8-hydroxylation of guanine bases of DNA by steroid estrogens: correlation of DNA damage by free radicals with metabolic acctivation to quinones. Carcinogenesis 16, 2571 (1995)
98. [97] Iverson, S. L., Shen, L., Anlar, N. et al., Bioactivation of estrone and its catechol metabolites to quinoid-glutathione conjugates in rat liver microsomes. Chem. Res. Toxicol. 9, 492 (1996)
99. [98] Metzler, M., Pfeiffer, E., Kohl, W. et al., Interactions of carcinogenic estrogens with microtubular proteins, in: Hormonal carcinogenesis, pp 86-94, J.J. Li, S. Nandi, S. A. Li (eds.), Springer-Verlag, New York (1992)
100. [99] Liehr, J. G., Ricci, M. J., 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc. Natl. Acad. Sci. USA 93, 3294 (1996)
101. [100] Castagnetta, L. A., Granata, O. M., Arcuri, F. P. et al., Gas chromatography/mass spectrometry of catechol estrogens. Steroids 57, 437 (1992)
102. [101] Liehr, J. G., Ricci, M. J., Jefcoate, C. R. et al., 4-Hydroxylation of estradiol by human uterine myometrium and myom microsomes: implications for the mechanism of uterine tumorigenesis. Proc. Natl. Acad. Sci. USA 92, 9220 (1995)
103. [102] Roy, D., Weisz, J., Liehr, L. G., The O-methylation of 4-hydroxyestradiol is inhibited by 2-hydroxyestradiol: implications for estrogen-induced carcinogenesis. Carcinogenesis 11, 459 (1990)
104. [103] Castagnetta, L. A., LoCasto, M., Granata, O. M. et al., Estrogen content and metabolism in human breast tumor tissues and cells. Ann. N.Y. Acad. Sci. 784, 314 (1996)
105. [104] Purohit, A., Reed, M. J., Morris, N. C. et al., Regulation and inhibition of steroid sulfatase activity in breast cancer. Ann. N.Y. Acad. Sci. 784, 40 (1996)
106. [105] Simpson, E. R., Zhao, Y., Estrogen biosynthesis in adipose. Significance in breast cancer development. Ann. N.Y. Acad. Sci. 784, 18 (1996)
107. [106] Schneider, J., Kinne, D., Fracchia, A. et al., Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc. Natl. Acad. Sci. USA 79, 3047 (1982)
108. [107] Fishman, J., Schneider, J., Hershcopf, R. J. et al, Increased estrogen 16-alpha hydroxylase activity in women with breast and endometrial cancer. J. Steroid Biochem. 20, 1077 (1984)
109. [108] Zumoff, B., Fishman, J., Cassouto, J. et al., Estradiol transformation in men with breast cancer. J, Clin. Endocrinol. 26, 960 (1966)
110. [109] Kabat, G. C., Chang, C. J., Sparano, J. A. et al., Urinary estrogen metabolites and breast cancer: A case-control study. Cancer Epidemiol. Biomarkers Prev. 6, 505 (1997)
111. [110] Bulard, J., Mowszowicz, J., Schaison, G., Increased aromatase activity in pubic skin fibroblasts from patients with isolated gynecomastia. J. Clin. Endocrinol. Metab. 64, 618 (1987)
112. [111] Bradlow, H. L., Arcuri, F., Blasi, L. et al., Effect of serum albumin on estrogen metabolism in human cancer cell lines. Mol. Cell Endocrinology 115, 221 (1995)
113. [112] Auborn, K. J., Woodworth, C., Dipaolo, J. et al., The interaction between HPV infection and estrogen metabolism in cervical carcinogenesis. Int. J. Cancer 49, 867 (1991)
114. [113] Bradlow, H. L., Sepkovic, D. W., Telang, N. T. et al., Indole-3-carbinol. A novel approach to breast cancer prevention. Ann. N.Y. Acad. Sci. 768, 180 (1995)
115. [114] Carruba, G., Miceli, M. D., Camito, L. et al., Multiple estrogen functions in human prostate cancer cells. Ann. N.Y. Acad. Sci. 784, 70 (1996)
116. [115] Zumoff, B., Freed, S. Z., Levin, J. et al., Metabolism of 3H-estradiol im men with prostate cancer. Eur. J. Cancer 16, 219 (1980)
117. [116] Steinberg, B. M., Abramson, A. L., Laryngeal papillomas. Clinics Dermatolog. 3, 130 (1985)
118. [117] Essman, E., Abramson, A., Estrogen binding sites on membranes from human laryngeal papilloma. Int. J. Cancer 33, 33 (1984)
119. [118] Newfield, L., Goldsmith, A., Bradlow, H. L. et al., Estrogen metabolism and human papilloma virus-induced tumors of the larynx. Anticancer Res. 13, 227 (1993)
120. [119] Coll, D. A., Rosen, C. A., Auborn, K. et al., Treatment of recurrent respiratory papillomatosis with indole-3-carbinol. Am. J. Otolaryngol. 18, 283 (1997)
121. [120] Rosen, C. A., Woodson, G. E., Tompson, J. W. et al., Preliminary results of the use of indole-3-carbinol for recurrent respiratory papillomatosis. Otolaryngol. Head Neck. Surg. 118, 810 (1998)
122. [121] Lippert, T. H., Seeger, H., Mueck, A. O., Estrogens and the cardiovascular system: role of estradiol metabolites in hormone replacement therapy. Climacteric 1, 296 (1999)
123. [122] Hyman, B., Muss, M. D., Endocrine therapy for advanced breast cancer: a review. Breast Cancer Res. Treat. 21, 15 (1992)